TESARO Draws $200 Million From Second Tranche of Non-Dilutive Term Loan Financing
29. Juni 2018 16:05 ET
|
TESARO, Inc.
WALTHAM, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has drawn the $200 million second tranche under...
TESARO Enters Asset Purchase Agreement with TerSera® Therapeutics LLC for VARUBI® in the U.S. and Canada
28. Juni 2018 16:05 ET
|
TESARO, Inc.
TESARO to Receive $40 Million, plus Potential for Additional Milestone Payments and Royalties TESARO Retains ex-North America Rights and Continues to Market VARUBY® in Europe WALTHAM, Mass., June ...
TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
05. Juni 2018 08:30 ET
|
TESARO, Inc.
WALTHAM, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with...
TESARO Summarizes TOPACIO and QUADRA Trial Results Presented at 2018 ASCO Annual Meeting
04. Juni 2018 18:00 ET
|
TESARO, Inc.
TOPACIO data for ZEJULA® (niraparib) in combination with an anti-PD-1 mAb highlight promising activity in platinum-resistant/refractory ovarian cancer and triple-negative breast cancer beyond patients...
TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
01. Juni 2018 03:00 ET
|
TESARO, Inc.
Inclusion in the Cancer Drugs Fund will give more women in England and Wales with recurrent, platinum-sensitive ovarian cancer access to ZEJULA via a managed access arrangementZEJULA was launched in...
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
16. Mai 2018 17:15 ET
|
TESARO, Inc.
Investor briefing to be webcast from Chicago on Monday, June 4, 2018 at 6:15PM CT WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical...
Psychological Effects of Ovarian Cancer Often Overlooked and Can Have a Significant Impact on Patients
08. Mai 2018 09:19 ET
|
TESARO, Inc.
79% of patients felt uncomfortable raising psychological and emotional concerns during their consultations1Disease recurrence is of greatest concern for ovarian cancer patients, but poorly addressed,...
TESARO Announces First-Quarter 2018 Operating Results
03. Mai 2018 16:05 ET
|
TESARO, Inc.
ZEJULA Q1 net sales totaled $49 millionEnrollment completed in Phase 3 PRIMA first-line ovarian cancer monotherapy trial TOPACIO platinum-resistant ovarian cancer and triple-negative breast cancer...
TESARO Announces Participation in Two Investor Conferences
01. Mai 2018 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....
TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA®
24. April 2018 07:00 ET
|
TESARO, Inc.
Results demonstrate ZEJULA activity beyond patients with BRCA mutations in late-line ovarian cancer treatment settingQUADRA data accepted for presentation at 2018 ASCO annual meetingData intended to...